Large cell differentiation of metastatic prostate cancer after androgen deprivation therapy

被引：1
|
作者：
Patel, Rutveej [1 ]
Faiena, Izak [1 ]
Geltzeiler, Jules [2 ]
机构：
[1] Rutgers Robert Wood Johnson Med Sch, Div Urol, New Brunswick, NJ USA
[2] Jersey Shore Univ, Med Ctr, Div Urol, Neptune, NJ USA
来源：
CANADIAN JOURNAL OF UROLOGY | 2015年 / 22卷 / 02期
关键词：
large cell neuroendocrine tumor; prostate cancer; hormone refractory prostate cancer; neuroendocrine differentiation; NEUROENDOCRINE DIFFERENTIATION;
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
We present a case of a 75-year-old male with a history of high risk prostate cancer who underwent androgen deprivation therapy and palliative radiation treatments for his disease. Subsequently, he presented with gross hematuria and severe lower urinary tract symptoms. A palliative transurethral resection of the prostate (TURP) at that time, demonstrated large cell differentiated neuroendocrine carcinoma with metastasis to the lung. We review the limited literature on this rare form of disease and present current treatment strategies.
引用
收藏
页码：7752 / 7754
页数：3
相关论文
共 50 条
  • [1] A Case of Metastatic Prostate Cancer to the Urethra That Resolved After Androgen Deprivation Therapy
    Bryk, Darren J.
    Angermeier, Kenneth W.
    Klein, Eric A.
    UROLOGY, 2019, 129 : E4 - E5
  • [2] SEX LIFE IN PATIENTS WITH METASTATIC PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY
    Ermec, Bahadir
    Taskapu, Hakan Hakki
    Dincer, Murat
    Ortac, Mazhar
    Salabas, Emre
    Kadioglu, Ates
    NOBEL MEDICUS, 2015, 11 (02): : 5 - 12
  • [3] Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer
    Hammerer, P.
    Manka, L.
    UROLOGE, 2019, 58 (10): : 1185 - 1197
  • [4] Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer
    Curtis, Kelly K.
    Pruthi, Rajiv K.
    Fonseca, Rafael
    Gornet, Michael K.
    UROLOGY, 2007, 70 (04) : 811.e5 - 811.e8
  • [5] Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence
    Ito, T
    Yamamoto, S
    Ohno, Y
    Namiki, K
    Aizawa, T
    Akiyama, A
    Tachibana, M
    ONCOLOGY REPORTS, 2001, 8 (06) : 1221 - 1224
  • [6] Use of androgen deprivation therapy for metastatic prostate cancer in older men
    Keating, Nancy L.
    O'Malley, A. James
    McNaughton-Collins, Mary
    Oh, William K.
    Smith, Matthew R.
    BJU INTERNATIONAL, 2008, 101 (09) : 1077 - 1083
  • [7] Successful downstaging of isolated bony metastatic prostate cancer after metastasectomy and androgen deprivation therapy
    Ting, Hui-Kung
    Cha, Tai-Lung
    Chang, Hung
    Liao, Yi-Shu
    Yu, Dah-Shyong
    FORMOSAN JOURNAL OF SURGERY, 2016, 49 (02) : 70 - 73
  • [8] Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer
    Wu, Szu-Yuan
    Fang, Su-Chen
    Hwang, Olivia Rachel
    Shih, Hung-Jen
    Shao, Yu-Hsuan Joni
    CANCERS, 2020, 12 (01)
  • [9] Immunohistochemical changes in prostate cancer after androgen deprivation therapy
    Bostwick, DG
    MOLECULAR UROLOGY, 2000, 4 (03) : 101 - 106
  • [10] Androgen Deprivation Therapy for Prostate Cancer
    Pagliarulo, Vincenzo
    MOLECULAR & DIAGNOSTIC IMAGING IN PROSTATE CANCER: CLINICAL APPLICATIONS AND TREATMENT STRATEGIES, 2019, 1126 : 1 - 30
12345